Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Takes Advantage Of COVID-19 Testing Rush

Executive Summary

Roche’s sales in 2020 increased by 1%, at constant exchange rates, to CHF 58.3bn, led by 14% growth in its diagnostics division.

You may also be interested in...



Diagnostics Saves Roche From Q1 Difficulties

In its first quarter 2021 sales earnings report, Roche highlighted the strength of its diagnostics business as biosimilars cannibalize its pharmaceutical revenues.

Roche Buys GenMark Diagnostics For $1.8Bn

GenMark’s syndromic panel testing portfolio complements Roche’s molecular diagnostics business.

FDA: Roche Test Flaws Could Misdiagnose Patients With COVID-19, Flu

The US agency has contacted health care providers to warn them about faulty COBAS SARS-CoV-2 and Influenza A/B Nucleic Acid Tests for use on the COBAS Liat System.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT143441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel